(Q50177933)

26 February 2018

title

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. (English)

1 reference

26 February 2018

1 reference

3

1 reference

26 February 2018

George Papatheodoridis

17

1 reference

26 February 2018

Dominique C Valla

26

1 reference

26 February 2018

Elisabeth Delarocque-Astagneau

8

object named as

E Delarocque-Astagneau

1 reference

26 February 2018

A Hatzakis

1

1 reference

26 February 2018

S Wait

2

1 reference

26 February 2018

M Buti

4

1 reference

26 February 2018

M Carballo

5

1 reference

26 February 2018

M Cavaleri

6

1 reference

26 February 2018

M Colombo

7

1 reference

26 February 2018

G Dusheiko

9

1 reference

26 February 2018

G Esmat

10

1 reference

26 February 2018

R Esteban

11

1 reference

26 February 2018

D Goldberg

12

1 reference

26 February 2018

C Gore

13

1 reference

26 February 2018

A S F Lok

14

1 reference

26 February 2018

M Manns

15

1 reference

26 February 2018

P Marcellin

16

1 reference

26 February 2018

A Peterle

18

1 reference

26 February 2018

D Prati

19

1 reference

26 February 2018

N Piorkowsky

20

1 reference

26 February 2018

M Rizzetto

21

1 reference

26 February 2018

F Roudot-Thoraval

22

1 reference

26 February 2018

V Soriano

23

1 reference

26 February 2018

H C Thomas

24

1 reference

26 February 2018

M Thursz

25

1 reference

26 February 2018

P van Damme

27

1 reference

26 February 2018

I K Veldhuijzen

28

1 reference

26 February 2018

H Wedemeyer

29

1 reference

26 February 2018

L Wiessing

30

1 reference

26 February 2018

A R Zanetti

31

1 reference

26 February 2018

H L A Janssen

32

1 reference

26 February 2018

publication date

1 September 2011

1 reference

26 February 2018

Journal of Viral Hepatitis

published in

1 reference

26 February 2018

volume

18 Suppl 1

1 reference

26 February 2018

page(s)

1-16

1 reference

26 February 2018

Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

The global impact of vaccination against hepatitis B: a historical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Are booster immunisations needed for lifelong hepatitis B immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Hepatitis B vaccination: to boost or not to boost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Access to health care for Roma children in Central and Eastern Europe: findings from a qualitative study in Bulgaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Case-reporting of acute hepatitis B and C among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Hepatitis C treatment for injection drug users: a review of the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Follow-up studies of treatment for hepatitis C virus infection among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

The impact of the prevention programme of hepatitis C over more than a decade: the French experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Market uptake of new antiviral drugs for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

Erhöhen Migrationen aus hohen und mittleren Endemiegebieten die Hepatitis B-Prävalenz in Deutschland?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01499.X

10.1111/J.1365-2893.2011.01499.X

21 January 2018

Identifiers

DOI

1 reference

26 February 2018

1 reference

26 February 2018